NEWS IN BRIEF
This article was originally published in The Silver Sheet
Executive SummaryFDA closes underused pilot Multipurpose Audit Program
You may also be interested in...
Genetic sequencing company Illumina is betting it can develop the first next-generation sequencing "pan-cancer" screening assay by building a separate company dedicated to the task. The new firm has $100 million in start-up funds and is called Grail.